TY - JOUR
T1 - Leucine-rich repeat kinase 2 expression leads to aggresome formation that is not associated with α-synuclein inclusions
AU - Waxman, Elisa A.
AU - Covy, Jason P.
AU - Bukh, Irene
AU - Li, Xiaojie
AU - Dawson, Ted M.
AU - Giasson, Benoit I.
PY - 2009/7
Y1 - 2009/7
N2 - Mutations in leucine-rich repeat kinase-2 (LRRK2) are the most common known cause of Parkinson disease, but how this protein results in the pathobiology of Parkinson disease is unknown. Moreover, there is variability in pathology among cases, and α-synuclein (α-syn) neuronal inclusions are often present, but whether LRRK2 is present in these pathological inclusions is controversial. This study characterizes novel LRRK2 antibodies, some of which preferentially recognize an aggregated form of LRRK2, as observed in cell culture models. Large perinuclear aggregates containing LRRK2 were promoted by proteasome inhibition and prevented by microtubule polymerization inhibition. Furthermore, they were vimentin- and γ-tubulin- but not lamp1-immunoreactive, suggesting that these structures fit the definition of aggresomes. Inhibition of heat shock protein 90 led to the degradation of only the soluble/cytosolic pool of LRRK2, suggesting that the aggresomes formed independent of the stability provided by the heat shock protein 90. Although these novel anti-LRRK2 antibodies identified aggregates in model cell systems, they did not immunostain pathological inclusions in human brains. Furthermore, coexpression of LRRK2 and α-syn did not recruit α-syn into aggresomes in cultured cells, even in the presence of proteasome inhibition. Thus, although LRRK2 is a model system for aggresome formation, LRRK2 is not present in α-syn pathological inclusions.
AB - Mutations in leucine-rich repeat kinase-2 (LRRK2) are the most common known cause of Parkinson disease, but how this protein results in the pathobiology of Parkinson disease is unknown. Moreover, there is variability in pathology among cases, and α-synuclein (α-syn) neuronal inclusions are often present, but whether LRRK2 is present in these pathological inclusions is controversial. This study characterizes novel LRRK2 antibodies, some of which preferentially recognize an aggregated form of LRRK2, as observed in cell culture models. Large perinuclear aggregates containing LRRK2 were promoted by proteasome inhibition and prevented by microtubule polymerization inhibition. Furthermore, they were vimentin- and γ-tubulin- but not lamp1-immunoreactive, suggesting that these structures fit the definition of aggresomes. Inhibition of heat shock protein 90 led to the degradation of only the soluble/cytosolic pool of LRRK2, suggesting that the aggresomes formed independent of the stability provided by the heat shock protein 90. Although these novel anti-LRRK2 antibodies identified aggregates in model cell systems, they did not immunostain pathological inclusions in human brains. Furthermore, coexpression of LRRK2 and α-syn did not recruit α-syn into aggresomes in cultured cells, even in the presence of proteasome inhibition. Thus, although LRRK2 is a model system for aggresome formation, LRRK2 is not present in α-syn pathological inclusions.
KW - Aggregation
KW - Aggresome
KW - Antibody
KW - LRRK2
KW - Parkinson disease
KW - α-Synuclein
UR - http://www.scopus.com/inward/record.url?scp=68249153855&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=68249153855&partnerID=8YFLogxK
U2 - 10.1097/NEN.0b013e3181aaf4fd
DO - 10.1097/NEN.0b013e3181aaf4fd
M3 - Article
C2 - 19535993
AN - SCOPUS:68249153855
SN - 0022-3069
VL - 68
SP - 785
EP - 796
JO - Journal of Neuropathology and Experimental Neurology
JF - Journal of Neuropathology and Experimental Neurology
IS - 7
ER -